Jeff Yass’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-11,087
| Closed | -$48.3K | – | 13472 |
|
|
2024
Q1 | $58.1K | Sell |
11,087
-37,509
| -77% | -$206K | ﹤0.01% | 11500 |
|
|
2023
Q4 | $254K | Buy |
48,596
+5,856
| +14% | +$57.8K | ﹤0.01% | 10181 |
|
|
2023
Q3 | $674K | Sell |
42,740
-14,266
| -25% | -$256K | ﹤0.01% | 7536 |
|
|
2023
Q2 | $1.11M | Sell |
57,006
-16,394
| -22% | -$389K | ﹤0.01% | 6441 |
|
|
2023
Q1 | $2.08M | Buy |
73,400
+54,449
| +287% | +$1.62M | ﹤0.01% | 5041 |
|
|
2022
Q4 | $554K | Buy |
18,951
+47
| +0.2% | +$1.5K | ﹤0.01% | 7593 |
|
|
2022
Q3 | $499K | Buy |
+18,904
| New | +$694K | ﹤0.01% | 8499 |
|
|
2022
Q2 | – | Sell |
-9,451
| Closed | -$468K | – | 14194 |
|
|
2022
Q1 | $468K | Sell |
9,451
-7,915
| -46% | -$380K | ﹤0.01% | 9166 |
|
|
2021
Q4 | $884K | Buy |
17,366
+7,597
| +78% | +$394K | ﹤0.01% | 7616 |
|
|
2021
Q3 | $545K | Buy |
9,769
+414
| +4% | +$20.4K | ﹤0.01% | 9154 |
|
|
2021
Q2 | $400K | Buy |
9,355
+3,398
| +57% | +$140K | ﹤0.01% | 10135 |
|
|
2021
Q1 | $249K | Buy |
+5,957
| New | +$277K | ﹤0.01% | 10996 |
|
|
2020
Q4 | – | Sell |
-6,372
| Closed | -$271K | – | 11863 |
|
|
2020
Q3 | $271K | Buy |
+6,372
| New | +$279K | ﹤0.01% | 8917 |
|
|
2020
Q2 | – | Sell |
-7,045
| Closed | -$351K | – | 11126 |
|
|
2020
Q1 | $324K | Buy |
+7,045
| New | +$354K | ﹤0.01% | 7830 |
|
|
2019
Q4 | – | Sell |
-9,317
| Closed | -$556K | – | 10848 |
|
|
2019
Q3 | $527K | Sell |
9,317
-6,586
| -41% | -$370K | ﹤0.01% | 7196 |
|
|
2019
Q2 | $885K | Buy |
15,903
+5,930
| +59% | +$309K | ﹤0.01% | 5951 |
|
|
2019
Q1 | $504K | Sell |
9,973
-11,674
| -54% | -$519K | ﹤0.01% | 6257 |
|
|
2018
Q4 | $872K | Buy |
+21,647
| New | +$1.12M | ﹤0.01% | 4948 |
|
|
2018
Q2 | – | Sell |
-3,835
| Closed | -$241K | – | 10599 |
|
|
2018
Q1 | $202K | Sell |
3,835
-17,543
| -82% | -$1.02M | ﹤0.01% | 8314 |
|
|
2017
Q4 | $1.14M | Buy |
+21,378
| New | +$1.19M | ﹤0.01% | 4964 |
|
|
2016
Q1 | – | Sell |
-33,053
| Closed | -$2.1M | – | 9811 |
|
|
2015
Q4 | $2.93M | Buy |
33,053
+1,255
| +4% | +$99.1K | ﹤0.01% | 3326 |
|
|
2015
Q3 | $2.35M | Buy |
31,798
+18,820
| +145% | +$1.57M | ﹤0.01% | 3956 |
|
|
2015
Q2 | $1.05M | Sell |
12,978
-16,764
| -56% | -$1.09M | ﹤0.01% | 6126 |
|
|
2015
Q1 | $1.25M | Buy |
+29,742
| New | +$844K | ﹤0.01% | 5314 |
|
Other funds holding EGRX
NCM
ACM
Jeff Yass's EGRX Position: Q2 2024 in Review
Jeff Yass sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 11,087 shares — an estimated $48.3K sold.
Jeff Yass first reported a position in EGRX in Q1 2015 and held it in 24 quarters. The position peaked at $2.93M in Q4 2015. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.
- Jeff Yass reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Jeff Yass sold 11,087 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $48.3K.
- Jeff Yass first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 24 quarters.
- Jeff Yass's Eagle Pharmaceuticals, Inc. position peaked at $2.93M in Q4 2015.
- 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.